The objective of this study is to describe how OECD Member Countries refer to value when making decisions on reimbursement and prices of new medicines. The study analysed reimbursement and pricing policies in 14 OECD countries (Australia, Belgium, Canada, Denmark, France, Germany, Italy, Japan, Korea, the Netherlands, Norway, Sweden, and the United Kingdom – England and Scotland). It also examined decisions made about 12 products brought to the market between 2005 and 2011 and chosen to illustrate differences across countries in how value is assessed and how this might affect reimbursement decisions and pricing outcomes.
The report describes methods used by countries to assess the therapeutic benefits of new products as well as approaches for economic evaluation, where relevant. It details how countries consider innovation, wider social benefits, severity or rarity of disease in their decisions, as well as the use of product-specific agreements.
Main results and conclusions
Health Working Paper No. 63: Value in Pharmaceutical Pricing (July 2013)
Country profiles will be published on this page at the end of 2013.
Ms. Valérie Paris: firstname.lastname@example.org
Pharmaceutical Pricing Policy project
OECD Review of Public Procurement of the Mexican Institute of Social Security